Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rabies VLP vaccine
- Development stage
- Unknown
- Lead developer
- Cadila Pharmaceuticals
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Oral, Intramuscular
01
Overview
The **rabies VLP vaccine** is a virus-like particle (VLP)-based subunit vaccine composed of self-assembled rabies virus glycoprotein (RVGP) and matrix protein (RVMP), mimicking the structure of the rabies virus to elicit robust humoral, cellular, and mucosal immune responses without replication risk. Developed primarily for rabies prevention, it demonstrates superior immunogenicity in preclinical models when formulated as an oral gut-targeted delivery using pH-responsive PLGA/Eudragit microparticles (EPLGA MPs) with adjuvant LTB, inducing high anti-RVGP IgG, IFN-γ, IL-4, CD4+/CD8+ T cells, and sIgA levels compared to controls or commercial vaccines like Rabisin. **Thrabis** (Cadila Pharmaceuticals) is a recombinant nanoparticle VLP version produced in Sf9 insect cells via baculovirus, approved for human use in a 3-dose regimen (days 0, 3, 7) for post-exposure prophylaxis, offering improved compliance over traditional 5-dose schedules.[1][2][4]
- Brand names
- Thrabis
- Other names
- RVLPsrecombinant rabies G protein vaccine
02
Targets
RABV-G (Rabies virus glycoprotein)
Beyond the preview
Go deeper on rabies VLP vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rabies VLP vaccine.